1. Home
  2. BCAB vs DAIO Comparison

BCAB vs DAIO Comparison

Compare BCAB & DAIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • DAIO
  • Stock Information
  • Founded
  • BCAB 2007
  • DAIO 1969
  • Country
  • BCAB United States
  • DAIO United States
  • Employees
  • BCAB N/A
  • DAIO N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • DAIO Electrical Products
  • Sector
  • BCAB Health Care
  • DAIO Industrials
  • Exchange
  • BCAB Nasdaq
  • DAIO Nasdaq
  • Market Cap
  • BCAB 28.6M
  • DAIO 26.9M
  • IPO Year
  • BCAB 2020
  • DAIO N/A
  • Fundamental
  • Price
  • BCAB $0.46
  • DAIO $3.04
  • Analyst Decision
  • BCAB Buy
  • DAIO Strong Buy
  • Analyst Count
  • BCAB 2
  • DAIO 1
  • Target Price
  • BCAB $5.00
  • DAIO $4.00
  • AVG Volume (30 Days)
  • BCAB 990.6K
  • DAIO 22.7K
  • Earning Date
  • BCAB 03-25-2025
  • DAIO 02-20-2025
  • Dividend Yield
  • BCAB N/A
  • DAIO N/A
  • EPS Growth
  • BCAB N/A
  • DAIO N/A
  • EPS
  • BCAB N/A
  • DAIO N/A
  • Revenue
  • BCAB $11,000,000.00
  • DAIO $23,458,000.00
  • Revenue This Year
  • BCAB N/A
  • DAIO N/A
  • Revenue Next Year
  • BCAB N/A
  • DAIO $0.21
  • P/E Ratio
  • BCAB N/A
  • DAIO N/A
  • Revenue Growth
  • BCAB N/A
  • DAIO N/A
  • 52 Week Low
  • BCAB $0.43
  • DAIO $2.29
  • 52 Week High
  • BCAB $4.02
  • DAIO $3.99
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 23.28
  • DAIO 58.63
  • Support Level
  • BCAB $0.46
  • DAIO $2.96
  • Resistance Level
  • BCAB $0.49
  • DAIO $2.98
  • Average True Range (ATR)
  • BCAB 0.04
  • DAIO 0.09
  • MACD
  • BCAB 0.03
  • DAIO 0.01
  • Stochastic Oscillator
  • BCAB 27.98
  • DAIO 71.43

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About DAIO Data I/O Corporation

Data I/O Corp is a provider of programming, security deployment, security provisioning and associated Intellectual Property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices and secure microcontrollers. It is engaged in focused on the design, manufacturing and sale of programming systems used by designers and manufacturers of electronic products. It has its geographic presence in United States, Europe and Rest of the world.

Share on Social Networks: